Akero Therapeutics Correlations
AKRO Stock | USD 52.08 2.25 4.14% |
The current 90-days correlation between Akero Therapeutics and Madrigal Pharmaceuticals is 0.29 (i.e., Modest diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Akero Therapeutics Correlation With Market
Average diversification
The correlation between Akero Therapeutics and DJI is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Akero Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Akero Stock
0.8 | PFE | Pfizer Inc | PairCorr |
0.66 | KMDA | Kamada | PairCorr |
0.82 | CGEN | Compugen | PairCorr |
0.65 | AVAL | Grupo Aval | PairCorr |
0.88 | KB | KB Financial Group Earnings Call This Week | PairCorr |
0.83 | SHG | Shinhan Financial Earnings Call This Week | PairCorr |
0.78 | WF | Woori Financial Group Earnings Call This Week | PairCorr |
0.81 | CSCO | Cisco Systems | PairCorr |
0.82 | IBM | International Business Earnings Call This Week | PairCorr |
0.63 | AA | Alcoa Corp | PairCorr |
0.81 | MSFT | Microsoft | PairCorr |
0.67 | CVX | Chevron Corp | PairCorr |
0.78 | DIS | Walt Disney | PairCorr |
0.7 | AXP | American Express | PairCorr |
Moving against Akero Stock
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Akero Stock performing well and Akero Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Akero Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ETNB | 2.83 | 0.91 | 0.24 | 4.19 | 2.62 | 6.63 | 22.76 | |||
MDGL | 2.12 | (0.11) | (0.02) | 0.06 | 2.38 | 4.31 | 11.12 | |||
PLRX | 3.34 | (0.08) | (0.01) | 0.07 | 4.37 | 6.67 | 18.42 | |||
ACLX | 1.96 | 0.12 | 0.02 | 0.30 | 3.80 | 4.14 | 21.92 | |||
STOK | 2.47 | 0.87 | 0.23 | 3.22 | 2.51 | 7.12 | 21.76 | |||
ALEC | 4.87 | 0.97 | 0.14 | 2.61 | 5.26 | 10.42 | 25.20 | |||
GOSS | 4.00 | 1.10 | 0.24 | 1.04 | 3.65 | 11.63 | 28.71 | |||
CABA | 4.98 | 0.58 | 0.11 | 0.46 | 5.82 | 12.15 | 64.76 |
Akero Therapeutics Corporate Management
Timothy Rolph | CoFounder Officer | Profile | |
Patrick Lamy | Senior Strategy | Profile | |
Scott Gangloff | Chief Officer | Profile | |
Catriona Yale | Executive Officer | Profile | |
Thomas Ross | Senior Legal | Profile | |
William JD | CFO, VP | Profile |